Ocena bezpieczeństwa i skuteczności cewnika do trombosapiracyjnego iNstroke 4F u pacjentów z ostrym niedokrwiennym udarem mózgu spowodowanym pierwotną niedrożnością dystalnych średnich naczyń (DMVO) (4-NiVO)
Prospektywne, jedno-ramienne, wieloośrodkowe badanie oceniające skuteczność i bezpieczeństwo cewnika tromboaspiracyjnego iNstroke 4F u pacjentów z ostrym niedokrwiennym udarem mózgu spowodowanym pierwotną okluzją dystalnych średnich naczyń (DMVO).
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This study is an exploratory, interventional, open label, single-arm, multi-centre prospective clinical investigation.
In this post-market clinical investigation, the aim is to further evaluate the efficacy and safety of the iNstroke 4F aspiration catheter, with a view to, in future clinical investigations, comparing the product with the standard therapy or with other similar products. In addition, this clinical investigation will generate results that could be used to further assess the safety and effectiveness of mechanical thrombectomy for the treatment of DMVO.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Barcelona, Hiszpania
- Hospital Universitario Vall d'Hebron
-
Madrid, Hiszpania
- Hospital Universitario 12 de Octubre
-
Madrid, Hiszpania
- Hospital Universitario La Paz
-
Madrid, Hiszpania
- Hospital Universitario de Getafe
-
Murcia, Hiszpania
- Hospital Clínico Universitario Virgen de Arrixaca
-
-
-
-
-
Bonn, Niemcy
- Universitätsklinikum Bonn
-
Kiel, Niemcy
- Universitätsklinikum Schleswig-Holstein
-
Marburg, Niemcy
- Klinikum Marburg
-
Nuremberg, Niemcy
- Klinikum Nürnberg
-
Recklinghausen, Niemcy
- Knappschaftskrankenhaus Recklinghausen
-
-
-
-
-
Budapest, Węgry
- Semmelweis University Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Subjects aged ≥ 18 years.
- Subjects with symptom onset up to 24 hours.
- Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
- Baseline NIHSS score ≥5 assessed before the procedure.
- Pre-stroke mRS score ≤ 2.
- Subjects with an ASPECTS score ≥ 6.
- Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
Exclusion Criteria:
- Subjects aged < 18.
- Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO.
- Baseline NIHSS score <5 assessed before the procedure.
- Pre-stroke mRS score >2.
- Subjects with an ASPECTS score <6.
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Medical history of thrombocytopenia (Platelets <100,000).
- Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
- Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy.
- Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months.
- Subjects participating in a clinical trial at the moment of the inclusion.
- Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Inny: Thromboaspiration using iNstroke 4F aspiration catheter
No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose. |
Patients to undergo thromboaspiration with iNstroke 4F |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Recanalization rate with a modified thrombolysis in cerebral infarction scale (mTICI) score ≥2b in ≤3 revascularization passes using iNstroke 4F aspiration catheter, alone or in conjunction with a SR. |
Intra-procedure
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of subjects treated with iNstroke 4F alone with complete recanalization in primary DMVO defined as an mTICI ≥2b, after iNstroke 4F aspiration catheter alone (ADAPT) was used as a first-line therapy |
Intra-procedure
|
|
Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of subjects treated with iNstroke 4F in conjunction with a stent retriever having complete recanalization in primary DMVO defined as achieving an mTICI ≥2b, after iNstroke 4F aspiration catheter, in conjunction with a stent retriever (SR), was used as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of subjects with mTICI≥2b, mTICI≥2c and mTICI 3 after first pass with iNstroke 4F aspiration catheter used both alone and in conjunction with a SR. |
Intra-procedure
|
|
Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Time from groin puncture to achievement of complete recanalization (mTICI ≥2b), or if not achieved, until the final angiogram time, in patients treated with iNstroke 4F aspiration catheter, alone or in conjunction with a SR, as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of subjects in which direct contact with thrombus is achieved with iNstroke 4F aspiration catheter. |
Intra-procedure
|
|
Clinical Endpoint
Ramy czasowe: 90 day
|
Proportion of subjects achieving a modified Rankin scale (mRS) score of 0-2 at the 90-day (±14 days) post-procedure follow-up visit. |
90 day
|
|
Safety Endpoint
Ramy czasowe: 24 (-8/+12) hours
|
Occurrence of SICH (according to SITS-MOST (13) and ECASS criteria (14)) within 24 (-8/+12) hours post-procedure, assessed by magnetic resonance imaging (MRI)/computed tomography (CT). Intracerebral Haemorrhage (ICH) is defined as the presence of extravascular blood in the brain or within the skull (local or remote parenchymal hematoma type 2, subarachnoid haemorrhage, and/or intraventricular haemorrhage) detected on the post-procedure imaging scan. ICH is considered symptomatic (SICH) if it is associated with a clinical deterioration, determined by a worsening/increase on the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points, or if it causes death and is identified as the predominant cause of neurological deterioration. |
24 (-8/+12) hours
|
|
Safety Endpoint
Ramy czasowe: Intra-procedure
|
Occurrence of embolization in a previously non-involved (or new) territory as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
Ramy czasowe: Intra-procedure
|
Occurrence of embolization in distal medium territory to the proximal occlusion as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
Ramy czasowe: During hospital admission
|
Inhospital mortality rate related to the procedure during hospital admission. |
During hospital admission
|
|
Safety Endpoint
Ramy czasowe: 90 days (±14 days) after the procedure.
|
Occurrence of devices and procedure related adverse events within 90 days (±14 days) after the procedure. |
90 days (±14 days) after the procedure.
|
|
Safety Endpoint
Ramy czasowe: Intra-procedure
|
Occurrence of procedure-related complications: arterial perforation, arterial dissection and severe vasospasm in the target vessel. |
Intra-procedure
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Exploratory Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of subjects in which a switch of technique (from ADAPT to combined or from combined to ADAPT) with iNstroke 4F aspiration catheter was used to successfully perform the thrombectomy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of subjects in which an aspiration catheter device with a 4F caliber different from iNstroke 4F aspiration catheter was used as a rescue therapy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Proportion of cases in which iNstroke 4F aspiration catheter (alone or in conjunction with a SR) successfully reached the site of occlusion. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Number of passes with iNstroke 4F aspiration catheter until recanalization. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
Ramy czasowe: Intra-procedure
|
Visibility of the catheter during the thrombectomy rated from 0 to 5 (being 0 the worst and 5 the best score). |
Intra-procedure
|
|
Exploratory Clinical Endpoint
Ramy czasowe: 24 (-8/+12) hours post-procedure.
|
Proportion of subjects with rapid neurological improvement, defined as a decrease of more than 4 points on the NIHSS scale, during the first 24 (-8/+12) hours post-procedure. |
24 (-8/+12) hours post-procedure.
|
|
Exploratory Clinical Endpoint
Ramy czasowe: First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
Proportion of subjects with a reduction of ≥8 points on the NIHSS scale during the first 24 (-8/+12) hours post-procedure, or with a NIHSS score of 0-1 at 3 days (±24 hours) or at the time of discharge, whichever occurs first. |
First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
|
Exploratory Clinical Endpoint
Ramy czasowe: 24 (-8/+12) hours.
|
Median of NIHSS score at 24 (-8/+12) hours. |
24 (-8/+12) hours.
|
|
Exploratory Clinical Endpoint
Ramy czasowe: 3 days (±24 hours) post procedure
|
Median of NIHSS score at 3 days (±24 hours) or at the time of patient discharge, whichever occurs first. |
3 days (±24 hours) post procedure
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 4-NiVO-01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .